Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

Healthcare Drug Manufacturers - Specialty & Generic
"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

VALEANT PHARMACEUTICALS INTL INC > One reason for Friday's sell-off
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(30)
•••
Post by domcolumbaon Jun 10, 2017 8:52pm
182 Views
Post# 26349474

One reason for Friday's sell-off

One reason for Friday's sell-offThere was an article in Barron's on Friday commenting on Wells Fargo analyst caution.

Valeant: What It Wants You to Ignore?

One analyst contends that investors should focus on Valeant's earnings per share, not its EBITDA.

https://www.barrons.com/articles/valeant-what-it-wants-you-to-ignore-1497034025?mod=yahoobarrons&ru=yahoo&yptr=yahoo

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities